SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 20th, 2014 • Protalex Inc • Services-commercial physical & biological research • New York
In addition, we or the FDA and/or foreign regulatory agencies may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if the FDA and/or foreign regulatory agencies find deficiencies in our IND and/or country specific regulatory submissions or in the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for future clinical trials.
PROTALEX, INC. Stock Option Agreement (this “Agreement”)Stock Option Agreement • February 20th, 2014 • Protalex Inc • Services-commercial physical & biological research
Protalex, Inc., a Delaware corporation (the “Company”), hereby grants to Kirk M. Warshaw (the “Optionee”), a stock option to purchase a total of 350,000 shares of the Company's Common Stock, par value $.00001 per share (the “Common Stock”), at a the price of $1.05 per share (the “Exercise Price”).
PROTALEX, INC. Stock Option Agreement (this “Agreement”)Stock Option Agreement • February 20th, 2014 • Protalex Inc • Services-commercial physical & biological research
Protalex, Inc., a Delaware corporation (the “Company”), hereby grants to Marco M. Elser (the “Optionee”), a stock option to purchase a total of 250,000 shares of the Company's Common Stock, par value $.00001 per share (the “Common Stock”), at a price of $9.00 per share (the “Exercise Price”).
